Know a great AI tool or AI news source? Submit it to AiByts

NeoCOAST-2

1 story

Stories

  • ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

    Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment1-3. NeoCOAST-2 (NCT05061550), a phase 2, randomised platform trial, tested novel perioperative treatments in patients with stage IIA–IIIB NSCLC.

    Nature AI5 min read

Showing 1 of 1 stories

You're all caught up.

AiByts Weekly Brief

Get the top AI news and tools straight to your inbox every week.

Weekly · AI news

Join 15,000+ AI enthusiasts